Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pedro J. Beltran
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 88
- Beta
- 0.36
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 5.10
Financials
Net Income
$-56.45MEBITDA
$-56.45MFree Cash Flow
$-44.41MEPS (diluted)
$-705.20Shares Outstanding (diluted)
80.1K-99.6%Operating Expenses
$60.19MCash & Debt
$225.71MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-134.04M | $-4.30 |
| 2024 | $0.00 | $-74.28M | $-5756.41 |
| 2023 | $0.00 | $-64.70M | $-0.00 |
| 2022 | $0.00 | $-3.5K | $0.00 |
| 2021 | $0.00 | $-43.4K | $-0.00 |
Valuation
BBOThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Positive
BBOT to Participate in Upcoming Investor Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.
View source ↗
Earnings
Wed, Nov 11(in 2 months)
Consensus estimate $-0.56 per share
Typical surprise -18.6% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.71 vs $-0.56miss
- Tue, May 12$-0.48 vs $-0.51beat
- Thu, Mar 5$-0.49 vs $-0.63beat
- Wed, Nov 12$-1.03 vs $-0.38miss
- Fri, Aug 1$-50.34 vs $-42.45miss
Estimates and results for BBOT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BBOT officers and directors.
No open-market trades in the recent filings. All 83 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.